D. E. Shaw & Co., Inc. Sarepta Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 4,478,638 shares of SRPT stock, worth $81.8 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
4,478,638
Previous 4,406
101548.62%
Holding current value
$81.8 Million
Previous $281,000
27154.09%
% of portfolio
0.06%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding SRPT
# of Institutions
468Shares Held
85.8MCall Options Held
5.14MPut Options Held
3.86M-
Black Rock Inc. New York, NY10.3MShares$189 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA4.7MShares$85.8 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$46.2 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.24MShares$41 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.6B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...